Patritumab Deruxtecan Biologics License Application for Patients with Previously Treated Locally Advanced or Metastatic EGFR-Mutated Non-Small Cell Lung Cancer Voluntarily Withdrawn The Biologics ...

Herbst: OK, next question. Let's talk about EGFR. There was a plenary talk in EGFR, the LAURA trial, and then there were a couple of studies looking at other ways to target EGFR. Let's start with the ...

Special Report: Race Oncology has taken a significant step forward in the clinical development of its next-generation cancer ...

Sac-TMT combined with Keytruda significantly improves progression-free survival in PD-L1-positive advanced non-small cell ...

A daily pill called osimertinib (Tagrisso) is delivering far longer cancer control for adults with unresectable stage 3 EGFR-mutated non-small cell lung cancer after chemoradiation and is now ...

AstraZeneca (NASDAQ:AZN) said its drug Tagrisso has been approved by EU regulators for the treatment of EGFR-mutation non-small cell lung cancer, or NSCLC. The European Commission approved Tagrisso ...

Blueprint Medicines is pulling back from one of its three areas of focus, dropping two non-small cell lung cancer (NSCLC) programs in response to early clinical data on the EGFR tyrosine kinase ...

A 75-year-old man with non-small cell lung cancer shows radiologic enlargement after neoadjuvant therapy; however, ...

Targeted therapies, guided by molecular testing, offer significant benefits, including fewer side effects and personalization ...

"Today's research is tomorrow's cure," said Upal Basu Roy, PhD, MPH, Executive Director of LUNGevity Research. "If we want to see continued breakthroughs and advancements in lung cancer, we must ...